Arbutus Biopharma Corp  (ABUS)
Other Ticker:  
Price: $2.8000 $-0.08 -2.778%
Day's High: $2.87 Week Perf: -4.11 %
Day's Low: $ 2.72 30 Day Perf: 13.82 %
Volume (M): 1,067 52 Wk High: $ 3.15
Volume (M$): $ 2,987 52 Wk Avg: $2.34
Open: $2.87 52 Wk Low: $1.69

 Market Capitalization (Millions $) 469
 Shares Outstanding (Millions) 168
 Employees 93
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -92
 Capital Exp. (TTM) (Millions $) 2

Arbutus Biopharma Corp
Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is a biotechnology company headquartered in Warminster, Pennsylvania, United States. The company has a focus on developing novel therapeutics that address hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and other liver diseases.

Their lead product candidate, AB-729, is a potentially first-in-class RNA interference (RNAi) therapeutic targeting HBV surface antigen, with the aim of achieving sustained virologic responses in patients. The drug utilizes Arbutus' proprietary GalNAc delivery technology, which is designed to specifically deliver RNAi agents to hepatocytes, the primary liver cells responsible for HBV replication.

Arbutus Biopharma operates a fully integrated research and development center in Burnaby, British Columbia, Canada, which includes chemistry and bioanalytical laboratories, as well as manufacturing facilities for clinical and commercial production of its drug products. The company has a strong intellectual property portfolio consisting of a variety of patents and patent applications that cover its drug candidates, delivery technologies and manufacturing processes.

The company has collaborations with a number of other biotech and pharmaceutical companies, including Roivant Sciences and Gritstone Oncology, aimed at developing RNAi therapies for the treatment of a variety of diseases. Arbutus also collaborates with the Baruch S Blumberg Institute, a renowned research institute based in Doylestown, Pennsylvania, to discover and develop new drug candidates for the treatment of liver diseases.

Arbutus Biopharma was founded in 2005 and went public in 201 The company is traded on the NASDAQ Global Market under the ticker symbol "ABUS".

   Company Address: 701 Veterans Circle Warminster 18974 PA
   Company Phone Number: 469-0914   Stock Exchange / Ticker: NASDAQ ABUS


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Arbutus Biopharma Corp Sets Stage for Medical Revolution with RNAi Therapeutic and Bold 2024 Objectives

Published Mon, Jan 8 2024 12:30 PM UTC

Arbutus Biopharma Corp: Charting a Bright Future with Groundbreaking RNAi TherapeuticArbutus Biopharma Corp, a leading biotechnology company, has recently unveiled its ambitious corporate objectives for 2024, along with an exciting financial update. The company aims to revolutionize the field of medicine with the development of its RNAi therapeutic, imdusiran, which is showi...

Arbutus Biopharma Corp

Arbutus Biopharma Corp Struggles Amidst Challenging Third Quarter of 2023

Arbutus Biopharma Corp, a major player in the pharmaceutical preparations industry, recently announced disappointing financial results for the period ending September 30, 2023. The company's shortfall per share advanced to -$0.12 from -$0.10 in Q2, while revenue plummeted by 21.741% to $4.66 million from $5.95 million the previous year. This decline in revenue stands in stark contrast to the rest of the sector, which experienced a top-line gain. As we delve deeper into Arbutus Biopharma Corp's financial performance, it becomes evident that the company is facing significant challenges.
Declining Revenue
One alarming aspect of Arbutus Biopharma Corp's financial results is the significant drop in revenue, which fell by 21.741% compared to the prior year. This decline is highly concerning, especially when other companies in the pharmaceutical preparations sector have managed to achieve substantial growth. Arbutus Biopharma Corp's inability to keep up with its competitors suggests underlying issues within the company, potentially pointing towards a lack of innovation or competitive advantage.

Arbutus Biopharma Corp

Arbutus Biopharma Corp Faces Surprising 67.341% Revenue Shock in Q2 2023: An Analysis of the Downturn

Arbutus Biopharma Corp, a biotechnology company specializing in the development of therapeutic solutions, has been recording progressively poor performance figures in recent financial quarters. The second quarter of 2023 has magnified the company's problems, with substantial losses and a significant decline in revenue. This bearish article will delve into the financial indicators and shed light on the challenges faced by Arbutus Biopharma Corp.
Revenue Plunge and Comparisons
During the second quarter of 2023, Arbutus Biopharma Corp's revenue suffered a substantial decline. The revenue plummeted by an alarming -67.341% to $4.65 million compared to $14.24 million in the same period last year. This deterioration signifies a significant setback for the company and indicates potential challenges in the product pipeline.

Arbutus Biopharma Corp

Arbutus Biopharma Corp Reports Improved Performance Despite Revenue Decline in Q1 2023

Arbutus Biopharma Corp recently announced its financial results for the time-frame closing March 31, 2023. The results showed a significant improvement in the company's performance compared to the previous year. Despite a decline in revenue, the company managed to decrease its loss per share, while boosting its EPS.
For this financial period, Arbutus Biopharma Corp decreased its loss per share to $-0.10, which was an improvement from the previous year's $-0.11 per share. The EPS also improved from $-0.11 per share from the prior reporting season. This shows that the company is beginning to turn the corner and moving in the right direction.


Arbutus Biopharma's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com